People prescribed a Jardiance or a Farxiga alongside a GLP-1 often type the same question into a search box: are these the same kind of drug? The honest answer is no, and further apart than the similar-looking names suggest. This page is the sibling of our article about DPP-4 inhibitors, and the pair exists because three drug classes get confused with GLP-1s for two different reasons. DPP-4 inhibitors get confused because they touch the same hormone system, which that article untangles. SGLT2 inhibitors get confused because they treat the same disease, from an entirely different direction.
What follows reads the current prescribing information for both classes: the mechanism first, then the indications, then the warnings, and then a refusal to rank. Because the second most common situation is not confusion at all; it is a medicine list carrying one drug from each class, prescribed together on purpose.
Where each class does its work
The mechanism on the SGLT2 labels is refreshingly concrete. SGLT2 is sodium-glucose co-transporter 2, and it is expressed in the proximal renal tubules, where it is responsible for the majority of the reabsorption of filtered glucose from the tubular lumen. In plain language: blood is filtered by the kidney, glucose lands in that filtrate, and this transporter's job is to pull almost all of it back into the blood rather than let it leave in the urine. An SGLT2 inhibitor reduces reabsorption of filtered glucose and lowers the renal threshold for glucose, and thereby increases urinary glucose excretion. The labels add that these drugs also reduce sodium reabsorption and increase the delivery of sodium to the distal tubule.
Now the contrast, which is the entire point. A GLP-1 receptor agonist works on the incretin system: it acts on insulin and glucagon secretion, slows gastric emptying, and reduces appetite. An SGLT2 inhibitor works in the kidney and sends glucose out in the urine. Different organ, different route, different everything downstream. One medicine changes how the body responds to a meal; the other changes what the kidney does with glucose that has already been filtered. Neither is a variant of the other.
The three products, and what each is approved for
Three SGLT2 inhibitors are marketed in the United States, and their indication lists are broader than most readers expect.
| Product | Molecule | Approved uses |
|---|---|---|
| Jardiance | Empagliflozin | Reducing the risk of cardiovascular death and hospitalization for heart failure in adults with heart failure. Reducing the risk of sustained decline in eGFR, end-stage kidney disease, cardiovascular death and hospitalization in adults with chronic kidney disease at risk of progression. Reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. Glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes. |
| Farxiga | Dapagliflozin | Reducing the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease at risk of progression. Reducing the risk of cardiovascular death, hospitalization for heart failure and urgent heart failure visit in adults with heart failure. Reducing the risk of hospitalization for heart failure in adults with type 2 diabetes and either established cardiovascular disease or multiple cardiovascular risk factors. Glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes. Not recommended for improving glycemic control in patients with type 1 diabetes. |
| Invokana | Canagliflozin | Glycemic control in adults and pediatric patients aged 10 and older with type 2 diabetes. Reducing the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease. Reducing the risk of end-stage kidney disease, doubling of serum creatinine, cardiovascular death and hospitalization for heart failure in adults with type 2 diabetes and diabetic nephropathy with albuminuria greater than 300 mg per day. |
Notice what runs through the table: heart failure and kidney disease appear again and again, in populations defined without requiring diabetes at all. The GLP-1 side of the comparison, product by product, is tabulated in What GLP-1s Are Actually Approved to Treat.
GLP 1 Tracker AppHowever many medicines your plan includes, a private, dated record of GLP-1 doses, side effects and weight, kept on your own phone.
Get the app
What the indication lists reveal
Two crossovers do not happen, and both are worth stating plainly. First: the heart failure and chronic kidney disease indications on Jardiance and Farxiga are not limited to people with diabetes. No GLP-1 product carries a heart failure indication. Second: no SGLT2 inhibitor on this list carries a weight-management indication, while several GLP-1 products do, and no GLP-1 works through the kidney the way these drugs do. The classes did not divide the same territory differently; they were built for overlapping but distinct jobs.
The kidney point needs one careful sentence, because it is where careless summaries go wrong. Ozempic's kidney indication and the SGLT2 kidney indications both exist, but they come from different trials in different populations and are not the same claim; the practical side of GLP-1s and kidney health, including the dehydration risk that matters on both classes, is covered in GLP-1s and Your Kidneys: Why Dehydration Is the Risk. An indication is a record of what was studied, not a trophy that transfers.
The warnings on these labels
The warnings on SGLT2 labels are genuinely different from the GLP-1 ones, because the mechanism is different. Diabetic ketoacidosis leads them, with an instruction that matters: assess for ketoacidosis regardless of presenting blood glucose levels. That is the label's way of saying the condition can appear without the high glucose people expect to accompany it, so the absence of a high reading does not rule it out.
Volume depletion follows, with an instruction to assess volume status and renal function before starting, particularly in older patients, those with impaired renal function and those on diuretics; the Invokana label adds that it may result in acute kidney injury. Then genitourinary infections, including urosepsis, pyelonephritis and genital mycotic infections, and a rare, serious one: necrotizing fasciitis of the perineum, called Fournier's gangrene, with an instruction to evaluate immediately anyone with pain, tenderness, erythema or swelling in the genital or perineal area along with fever or malaise. Hypoglycemia appears as a risk when these drugs are combined with insulin or an insulin secretagogue.
Two more label facts complete the picture. A lower limb amputation warning appears on the Invokana label specifically, in its section on monitoring patients for infections or ulcers of the lower limb; it is not in the warnings list on the Farxiga or Jardiance labels, and it should not be generalized to the class. And none of the three carries a boxed warning, while the GLP-1 class does, about thyroid C-cell tumors, explained in The Boxed Warning on Your GLP-1 Label, Explained.
Two classes, often together
The most important paragraph is the least dramatic. Being prescribed a GLP-1 and an SGLT2 inhibitor at the same time is common, and it is not a mistake: the classes work in different places, and prescribers use them together in managing type 2 diabetes and related conditions. Any question about combining them, stopping either one, or changing anything on the list belongs to the prescriber who manages the whole picture, and nothing in this article should be read as nudging that decision in either direction.
For readers keeping the full family straight, the third confusable class sits closer to the GLP-1s than this one does. The DPP-4 inhibitors touch the same hormone system, which is exactly why they get mistaken for GLP-1s; that comparison, mechanism by mechanism, is in DPP-4 Inhibitors: The Other Way to Raise GLP-1. Three classes, three reasons for the confusion, and one habit that resolves all of them: read the label for the product actually in the box.
Frequently asked questions
Is Jardiance a GLP-1 medication?
No. Jardiance, generic name empagliflozin, is an SGLT2 inhibitor, a completely different class. It works in the kidney, blocking a transporter that reabsorbs filtered glucose back into the blood, so glucose leaves in the urine instead. A GLP-1 receptor agonist works on the incretin system, acting on insulin and glucagon secretion, gastric emptying and appetite. Both treat type 2 diabetes, and a person can be prescribed both, but they are different drugs doing different jobs.
Can you take an SGLT2 inhibitor with a GLP-1?
Yes, being on both is common and is not a mistake. The two classes have different mechanisms in different organs, and prescribers combine them routinely in the management of type 2 diabetes and related conditions. Whether the combination, or any change to it, fits a particular person is a prescriber decision, and this article does not build a case either way. If your list includes both, that is a plan, not an error.
Do SGLT2 inhibitors cause weight loss?
None of the three products discussed here, Jardiance, Farxiga and Invokana, carries a weight management indication; their approved uses concern blood sugar, the heart, the kidneys, or combinations of those. That is a statement about the labels, not a comparison of results between classes, and no GLP-1 works through the kidney the way these drugs do. Equally, no SGLT2 inhibitor carries a weight management indication while several GLP-1 products do. Which class fits which goal belongs to a prescriber.
What is the main difference between how the two classes work?
The organ. SGLT2 is a transporter expressed in the proximal renal tubules, responsible for the majority of the reabsorption of filtered glucose. Blocking it increases urinary glucose excretion, and these drugs also reduce sodium reabsorption and increase sodium delivery to the distal tubule. A GLP-1 receptor agonist instead acts on the incretin system, influencing insulin and glucagon secretion, slowing gastric emptying and reducing appetite. Different organ, different route, and different everything downstream.
Which warnings are specific to SGLT2 inhibitors?
The labels warn about diabetic ketoacidosis, with an instruction to assess for it regardless of presenting blood glucose levels; volume depletion, with assessment of volume status and renal function before starting, particularly in older patients and those on diuretics; serious genitourinary infections, including rare necrotizing fasciitis of the perineum; and hypoglycemia when combined with insulin or an insulin secretagogue. A lower limb amputation warning appears on the Invokana label specifically, not the other two. None of the three carries a boxed warning, while the GLP-1 class does, about thyroid C-cell tumors.